SAB BIOTHERAPEUTICS INC (SABS) Stock Price, Quote, News and Overview
NASDAQ:SABS - Nasdaq - US78397T2024 - Common Stock
SABS Quote and Key Statistics
SAB BIOTHERAPEUTICS INC
NASDAQ:SABS (1/22/2025, 2:29:54 PM)
3.75
+0.08 (+2.18%)
SABS Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.7% | ||
| ROE | -123.48% | ||
| Debt/Equity | 0.09 |
SABS Performance and Technical Analysis
SABS Ownership and Analysts
SABS Latest News and Analysis
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update...
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel...
About SABS
Company Profile
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. The company is headquartered in Miami Beach, Florida and currently employs 57 full-time employees. The company went IPO on 2021-01-12. The firm's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The firm's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.
Company Info
SAB BIOTHERAPEUTICS INC
777 W 41St St, Suite 401
Miami Beach FLORIDA US
CEO: Samuel J. Reich
Employees: 57
Company Website: https://www.sab.bio/
Investor Relations: https://ir.sabbiotherapeutics.com/
Phone: 13058452813
SABS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.83 | 300.64B | ||
| AMGN | AMGEN INC | 14.28 | 147.57B | ||
| GILD | GILEAD SCIENCES INC | 21.02 | 116.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 842.12 | 110.60B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.07 | 75.24B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.27B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.69B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.39B | ||
| NTRA | NATERA INC | N/A | 22.64B | ||
| BIIB | BIOGEN INC | 8.74 | 20.80B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.57B |